Abstract
A national survey of Bacteroides fragilis group was continued in 1989 for the ninth consecutive year. Seven hundred thirty-nine isolates of B fragilis group from eight centers were tested for susceptibility to 14 antimicrobials. Sulbactam and clavulanic acid, beta-lactamase inhibitors, were tested at a constant concentration of 8 μg/ml and 2 μg/ml, respectively. Sulbactam was also tested in a fixed ratio of 1:2. Imipenem, ampicillin + sulbactam, and ticarcillin + clavulanic acid had resistance of < 1% at breakpoints of 8 μg/ml, 16 μg/ml, and 64 μg/ml, respectively. At 32 μg/ml, resistance to cefoxitin, cefotetan, ceftizoxime, and ceftriaxone were 4%, 25%, 26%, and 46%, respectively. Clindamycin resistance was 10% at a breakpoint of 4 μg/ml. No isolates were resistant to chloramphenicol or metronidazole. Resistance for five B fragilis species to cefoxitin, ceftizoxime, and cefotetan varied greatly among both species and participating institutions. The addition of a beta-lactamase inhibitor increased the potency of the betalactam drugs tested as combinations. This finding suggests that beta-lactamase production is the major resistance factor in members of the B fragilis group.
| Original language | English |
|---|---|
| Pages (from-to) | 122-136 |
| Number of pages | 15 |
| Journal | Clinical Therapeutics |
| Volume | 14 |
| Issue number | 1 |
| State | Published - Apr 22 1992 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989. / Cuchural, G. J.; Snydman, D. R.; McDermott, L.; Iannini, P. B.; Hill, G. B.; Cleary, Timothy; O'Keefe, J. P.; Pierson, C. L.; Rihs, J. D.; Finegold, S. M.
In: Clinical Therapeutics, Vol. 14, No. 1, 22.04.1992, p. 122-136.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989
AU - Cuchural, G. J.
AU - Snydman, D. R.
AU - McDermott, L.
AU - Iannini, P. B.
AU - Hill, G. B.
AU - Cleary, Timothy
AU - O'Keefe, J. P.
AU - Pierson, C. L.
AU - Rihs, J. D.
AU - Finegold, S. M.
PY - 1992/4/22
Y1 - 1992/4/22
N2 - A national survey of Bacteroides fragilis group was continued in 1989 for the ninth consecutive year. Seven hundred thirty-nine isolates of B fragilis group from eight centers were tested for susceptibility to 14 antimicrobials. Sulbactam and clavulanic acid, beta-lactamase inhibitors, were tested at a constant concentration of 8 μg/ml and 2 μg/ml, respectively. Sulbactam was also tested in a fixed ratio of 1:2. Imipenem, ampicillin + sulbactam, and ticarcillin + clavulanic acid had resistance of < 1% at breakpoints of 8 μg/ml, 16 μg/ml, and 64 μg/ml, respectively. At 32 μg/ml, resistance to cefoxitin, cefotetan, ceftizoxime, and ceftriaxone were 4%, 25%, 26%, and 46%, respectively. Clindamycin resistance was 10% at a breakpoint of 4 μg/ml. No isolates were resistant to chloramphenicol or metronidazole. Resistance for five B fragilis species to cefoxitin, ceftizoxime, and cefotetan varied greatly among both species and participating institutions. The addition of a beta-lactamase inhibitor increased the potency of the betalactam drugs tested as combinations. This finding suggests that beta-lactamase production is the major resistance factor in members of the B fragilis group.
AB - A national survey of Bacteroides fragilis group was continued in 1989 for the ninth consecutive year. Seven hundred thirty-nine isolates of B fragilis group from eight centers were tested for susceptibility to 14 antimicrobials. Sulbactam and clavulanic acid, beta-lactamase inhibitors, were tested at a constant concentration of 8 μg/ml and 2 μg/ml, respectively. Sulbactam was also tested in a fixed ratio of 1:2. Imipenem, ampicillin + sulbactam, and ticarcillin + clavulanic acid had resistance of < 1% at breakpoints of 8 μg/ml, 16 μg/ml, and 64 μg/ml, respectively. At 32 μg/ml, resistance to cefoxitin, cefotetan, ceftizoxime, and ceftriaxone were 4%, 25%, 26%, and 46%, respectively. Clindamycin resistance was 10% at a breakpoint of 4 μg/ml. No isolates were resistant to chloramphenicol or metronidazole. Resistance for five B fragilis species to cefoxitin, ceftizoxime, and cefotetan varied greatly among both species and participating institutions. The addition of a beta-lactamase inhibitor increased the potency of the betalactam drugs tested as combinations. This finding suggests that beta-lactamase production is the major resistance factor in members of the B fragilis group.
UR - http://www.scopus.com/inward/record.url?scp=0026549348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026549348&partnerID=8YFLogxK
M3 - Article
C2 - 1576621
AN - SCOPUS:0026549348
VL - 14
SP - 122
EP - 136
JO - Clinical Therapeutics
JF - Clinical Therapeutics
SN - 0149-2918
IS - 1
ER -